Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.70 |
| ▸ | IDO1 | P14902 | 2/20 | 0.58 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | PGK1 | P00558 | 1/20 | 0.47 |
| ▸ | PGK2 | P07205 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5983768 | 0.85 | AKR1C3 (0.74) | AKR1C3IDO1LOXL2MAOBPGK1 | |
| SCHEMBL4989626 | 0.83 | AKR1C3 (0.53) | AKR1C3IDO1LOXL2TSHRCA1 | |
| SCHEMBL10568121 | 0.83 | AKR1C3 (0.66) | AKR1C3IDO1LOXL2MAOBPGK1 | |
| SCHEMBL11544092 | 0.82 | AKR1C3 (0.70) | AKR1C3IDO1LOXL2MAOBPGK1 | |
| SCHEMBL5069158 | 0.82 | AKR1C3 (1.00) | AKR1C3IDO1LOXL2MAOBPGK1 | |
| SCHEMBL10766432 | 0.82 | AKR1C3 (0.70) | AKR1C3IDO1LOXL2MAOBPGK1 | |
| SCHEMBL5983772 | 0.82 | AKR1C3 (0.81) | AKR1C3IDO1LOXL2MAOBPGK1 | |
| SCHEMBL18086502 | 0.82 | AKR1C3 (0.52) | AKR1C3IDO1MAOBRAB9ANPC1 | |
| SCHEMBL8062311 | 0.81 | IDO1 (0.70) | AKR1C3IDO1LOXL2MAOBRAB9A | |
| SCHEMBL8779946 | 0.79 | AKR1C3 (0.71) | AKR1C3IDO1LOXL2MAOBPGK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118599281-B | Composite material for 3D printing and preparation method thereof | 深圳永昌和科技有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-118367216-B | Sodium ion battery electrolyte | 吉安冠佳新能源开发有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-118599281-A | Composite material for 3D printing and preparation method thereof | 深圳永昌和科技有限公司 | 2024-09-06 | — | — | CN | claimed |
| CN-118367216-A | Sodium ion battery electrolyte | 吉安冠佳新能源开发有限公司 | 2024-07-19 | — | — | CN | claimed |
| EP-0998518-B1 | PROCESS FOR THE PREPARATION OF POLYETHER PHOSPHATES | AMERSHAM HEALTH AS (NO) | 2003-12-10 | — | — | EP | claimed |
| US-6500917-B1 | REACTING SUCH AS POLYETHYLENE GLYCOL WITH A DIARYL- OR DIARALKYL- HALOPHOSPHATE AND REDUCTIVELY CLEAVING ARYL GROUPS; PHOSPHATE MODIFICATION WITH LOW IMPURITIES | AMERSHAM HEALTH AS (NO) | 2002-12-31 | — | — | US | claimed |
| EP-0998518-A1 | PROCESS FOR THE PREPARATION OF POLYETHER PHOSPHATES | NYCOMED IMAGING AS (NO) | 2000-05-10 | — | — | EP | claimed |
| WO-1999005200-A1 | PROCESS FOR THE PREPARATION OF POLYETHER PHOSPHATES | NYCOMED IMAGING AS (NO) | 1999-02-04 | — | — | WO | claimed |
| EP-4744667-A2 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | The Queen's University Of Belfast (GB) | 2026-05-20 | — | — | EP | disclosed |
| US-20250163093-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2025-05-22 | — | — | US | disclosed |
| CN-110662542-B | Nicotinoyl nucleosides and reduced nicotinoyl nucleosides, modified derivatives thereof, phosphorylated analogs thereof, adenosine dinucleotide conjugates thereof, and efficient and scalable synthesis of novel crystalline forms thereof | 英国贝尔法斯特女王大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-118599281-B | Composite material for 3D printing and preparation method thereof | 深圳永昌和科技有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119320417-A | Nicotinoyl nucleosides and reduced nicotinoyl nucleosides, modified derivatives thereof, phosphorylated analogs, adenosine dinucleotide conjugates, and efficient and scalable synthesis of novel crystalline forms | 英国贝尔法斯特女王大学 | 2025-01-17 | — | — | CN | disclosed |
| US-12195494-B2 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2025-01-14 | — | — | US | disclosed |
| US-4208330-A | ANTIBIOTICS, BACTERICIDES | MERCK & CO., INC. (US) | 1980-06-17 | — | — | US | disclosed |
| US-4196211-A | ANTIBIOTIC | MERCK & CO., INC. (US) | 1980-04-01 | — | — | US | disclosed |
| US-4194047-A | Substituted N-methylene derivatives of thienamycin | MERCK & CO., INC. (US) | 1980-03-18 | — | — | US | disclosed |
| US-4172144-A | Schiff's base derivatives of thienamycin | MERCK & CO., INC. (US) | 1979-10-23 | — | — | US | disclosed |
| US-4150145-A | ANTIBIOTIC, BACTERICIDES | MERCK & CO., INC. (US) | 1979-04-17 | — | — | US | disclosed |
| EP-0001265-A1 | O-, N- and carboxyl derivatives of thienamycin sulfoxide and sulfone, their preparation and pharmaceuticals containing said compounds | MERCK & CO. INC. (US) | 1979-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163093-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | NAPRT, NAMPT, CD38 | AKR1C3 633/4885IDO1 3273/4885LOXL2 3919/4885 |
| US-12195494-B2 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | NAPRT, NAMPT, CD38 | AKR1C3 633/4885IDO1 3273/4885LOXL2 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.